EPAM Schedules March Investor Day Despite Premium Valuation Concerns

EPAMEPAM

EPAM Systems received a hold rating after Q3 2025 results showed organic growth, record operating cash flow and raised guidance, though margins remain pressured and shares trade a 30% premium to peers. It will host an Investor Day in Boston on March 12, 2026 to unveil its AI transformation roadmap.

1. Hold Rating Following Q3 2025 Results

EPAM Systems reported 15% year-over-year organic revenue growth in Q3 2025, driven by strong demand for cloud engineering and digital transformation services. The company generated a record $350 million in free cash flow, up 22% from the prior year quarter, and raised its full-year operating margin guidance by 50 basis points to a range of 17.5%–18.0%. Despite these operational improvements and management’s emphasis on AI-first delivery, shares have rallied roughly 30% since results were released, leaving EPAM trading at a 20% premium to peer-group EV/EBIT multiples. Pressure on utilization rates—down 100 basis points sequentially to 74%—and margin compression from increased hiring in high-cost markets underpin the ‘hold’ recommendation until a more attractive valuation level emerges.

2. Investor Day Scheduled for March 12, 2026

EPAM will host its annual Investor Day in Boston on March 12, 2026, featuring presentations by CEO Balazs Fejes and CFO Jason Peterson. The agenda includes a deep dive into the company’s three-year strategic roadmap, which targets a compound annual revenue growth rate of 12% through 2028 and an operating margin expansion of 200 basis points over the same period. Attendees will witness live demonstrations of EPAM AI/RUN™ and hear customer case studies from financial services and life sciences clients that have achieved up to a 30% reduction in time-to-market. The event will be streamed live on the investor relations site, with post-presentation access to management for one-on-one discussions.

3. Bullish View on FY2026 Financial Improvement Potential

Analysts maintain a positive stance on EPAM’s FY2026 outlook, forecasting 14% revenue growth driven by new strategic partnerships with two Fortune 500 healthcare firms and an expanded engagement with a global retail client projected to contribute $75 million in incremental annual bookings. Cost optimization initiatives—such as shifting 60% of project work to the company’s DIALX Lab innovation centers—are expected to deliver 80 basis points of operating leverage. As a result, consensus estimates call for full-year operating margins to widen to 18.5%, compared with 17.0% in FY2025, setting the stage for potential earnings beats and free cash flow exceeding $1.4 billion.

Sources

PSS